Skip to content

Clinical Trial to Asessment Efficacy and Safety of WHS on the skin wrinkle improvement and moisturizing

Efficacy and Safety of WHS on the skin wrinkle improvement and moisturizing; A 12week, Randomized, Double-blind, Placebo-Controlled Clinical Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0003625
Enrollment
150
Registered
2019-03-14
Start date
2018-12-12
Completion date
Unknown
Last updated
2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Subjects are randomly assigned and divided into test groups 1, test groups 2, and control groups. In test group 1, 300mg of hydrangea leaf extract, which is a test food, is taken

Sponsors

COSMAX BIO
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Men and women aged 35 and over 60 years old (2) A person who is rated 3 grade with a diameter of wrinkle in thr eyes or higher in a visual evaluation (3) Measure the moisture content of both cheeks using corneometer® and measure the average score of 49 points or less. (4) A person who agrees to participate in this clinical trial test before the commencement of the clinical trial and has signed the written consent

Exclusion criteria

Exclusion criteria: (1) A person who suffers or is currently undergoing treatment from skin diseases such as atopic dermatitis and psoriasis. (2) Any person who is sensitive or allergic to food for testing (3) A person who experiences skin problems such as spots, pimples, iris, and capillary expansion at the test site (4) A person who received treatment on the face (skin stripping, chemical peeling, other skin care, etc.) within one month of the beginning of a test or treatment on the face of botox, filler, etc. within six months (5) A person who uses a steroid-containing skin ophthalmoid on the face or takes an systemic retinoid/steroid within three months of testing (6) A person who used functional cosmetics (retinoid agents, retinol, AHA) or highly moisturized cosmetics to improve wrinkles within two weeks from the start of a test (7) A person who has taken diet pills (absorbent and antidepressants, appetite suppressants, etc.), birth control pills or hormone medications, and diuretic medications within one month of testing (8) A person who has taken antioxidants, hyaluronic acid, health function foods containing collagen, drug medicines or health function foods containing evening primrose seed oil, vitamin A, vitamin C, vitamin E within two weeks of testing (9) AST (GOT) or ALT (GPT) greater than 120 IU/L or ?-GTP greater than 180 IU/L. (10) A person whose creatine is 2.4 mg/dL or higher (11) not more than 0.1 µIU/ml of TSH or more than 10 µIU/ml (12) High blood pressure unadjusted (160/100mmHg or higher, based on measurement after 10 minutes of stabilization) (13) Diabetic patients with no blood sugar adjusted (greater than 180 mg/dl per fasting glucose) (14) Mental patients with schizophrenia, depression, and drug addiction (15) A person who is pregnant, nursing or planning to become pregnant within three months (16) A person inpatients, medications, and rehabilitating for alcohol use, induced disability, heart disease, and central neurological disorder through a medical history survey (17) Smokers or persons less than one year after quitting smoking. (18) A person who participated in another clinical trial within one month of the start of the test or who is planning to participate during the test period; (19) A person who participated in the same clinical trial within six months of the beginning of the test or who is planning to participate during the test period; (20) A person who is deemed inappropriate by the tester for this test

Design outcomes

Primary

MeasureTime frame
Skin wrinkling;Skin moisture

Secondary

MeasureTime frame
Loss of skin moisture;Skin elasticity;Skin texture;Roughness of skin;Improvement of the tester;Improvement of the test subjects;Abnormal events;clinical pathological examination(hematological/hemochemical examination, urinalysis);Vital signs;physical measurement(body weight)

Countries

Korea, Republic of

Contacts

Public ContactLee Hoon

Global Medical Research Center

kwanglee@gmrc.co.kr+82-2-517-0877

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026